Assessment of Efficiency of Nebulized Ceftazidime and Amikacine in Patients with Pneumonia Caused byPseudomonas aeruginosa.

Nebulized Ceftazidime and Amikacin in Ventilator-associated Pneumonia Caused by Pseudomonas aeruginosa

“…Secondary endpoints included antibiotic-induced changes of lung aeration and lung inflammation assessed by computed tomography scan and per-treatment emergence of resistant strains. Some of the results of this study have been previously reported in the form of an abstract (11).…”

“…It was defined as the increase in gas volume in each lung region of interest following 8-day treatment. (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23) 0.08 Mortality at day 28, n (%) 2(10%) 1(5%) 0.55 Cure of VAP= association of reduction of clinical and biological signs of infection, decrease in CPIS below 6, significant lung CT reaeration and lower respiratory tract specimens either sterile or with nonsignificant concentrations of P aeruginosa. Persisting VAP = lack of improvement of clinical and biological signs, CPIS greater than 6, absence of CT lung reaeration with significant concentrations of P aeruginosa persisting in lower respiratory tract specimens.…”

“…Daily dose (mg.kg -1 ) 15.7* 15.0 C peak (mg.L -1 ) 8.9 (5)(6)(7)(8)(9)(10)(11) 45.1 <0.001 C trough (mg.L -1 ) 2.4 (1.7-5.9) 3.3 (1.9-5.8) 0.742 C peak = Peak plasma concentrations measured 30 min after completion of nebulization or immediately at the end of the intravenous bolus administration; C trough = Trough plasma concentrations measured immediately before the next nebulization, immediately before intravenous bolus administration or at any time in patients receiving continuous intravenous ceftazidime administration; IV = Intravenous; * = Dose reaching the respiratory system according to ceftazidime and amikacin extrapulmonary deposition. Data are expressed as mean±SD or median (25-75% interquartile range) according to data distribution.…”

Aerolized antibiotics in patients with ventilator-associated pneumonia

“…и MRSA у пациентов с муковисцидозом [35]. В исследовании I фазы продемонстрирована высокая безопасность комбинации фосфомицина и амикацина у больных с ВАП, кроме того, доказана возможность достижения высоких концентраций антибиотиков в трахеальных аспиратах при их низких концентрациях в плазме крови [36].…”